Cargando…
Synthetic cathinone (α-pyrrolidinohexanophenone): an emerging threat
INTRODUCTION: Alpha-pyrrolidinohexanophenone (α-PHP) is a synthetic cathinone with uneven distribution throughout the world. Its use is not uniformly regulated and its distribution is legal in some European countries. Easily accessible and available through different websites. Synthetic cathinones i...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9565950/ http://dx.doi.org/10.1192/j.eurpsy.2022.1193 |
_version_ | 1784809018612514816 |
---|---|
author | Rosello-Molina, V. Hervas Aparisi, A. Simon Blanes, M. Tejera Nuñez, J. Moreno Soldado, E. Meri Abad, I. Sparano Ros, O. Ribera, C. Esteban, M. De Vicente Muñoz, T. |
author_facet | Rosello-Molina, V. Hervas Aparisi, A. Simon Blanes, M. Tejera Nuñez, J. Moreno Soldado, E. Meri Abad, I. Sparano Ros, O. Ribera, C. Esteban, M. De Vicente Muñoz, T. |
author_sort | Rosello-Molina, V. |
collection | PubMed |
description | INTRODUCTION: Alpha-pyrrolidinohexanophenone (α-PHP) is a synthetic cathinone with uneven distribution throughout the world. Its use is not uniformly regulated and its distribution is legal in some European countries. Easily accessible and available through different websites. Synthetic cathinones inhibit monoamine transporters which include dopamine, norepinephrine, and serotonin, resulting in increased neurotransmitter synaptic concentration. Ways of administration show wide range regarding latency period. Onset and appearance of symptoms as well as their duration and intensity may fluctuate. A decreasing order of latency (oral, inhaled, sublingual and intravenous) has been reported. α-PHP can result in the appearance of psychiatric symptoms, include among others, intoxication with sensory perception disturbances and α-PHP -induced psychotic episodes. OBJECTIVES: The aim of our study was to assess the epidemiology, clinical and legal features regarding Alpha-pyrrolidinohexanophenone (α-PHP). METHODS: Review the current bibliography to upgrade the existing knowledge. -Present assorted cases with diverse clinical features. All cases include variability through psychopathological interview, symptoms assessment and treatment response according to rating scales (PANSS, YMRS). -Evaluate different treatment administration ways during acute phase and after hospital discharge. RESULTS: Differences were observed after hospitalization in the response using diverse rating scales. We used antipsychotics to treat intoxication with sensory perception disturbances and α-PHP -induced psychotic episodes. α-PHP had a negative impact on the quality of life of the patients. CONCLUSIONS: α-PHP is a synthetic cathinone with potential risk to mental health and life of users. It is mandatory to implement common legislation all through the European Union to prevent its use and possible implications on population’s mental health. DISCLOSURE: No significant relationships. |
format | Online Article Text |
id | pubmed-9565950 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95659502022-10-17 Synthetic cathinone (α-pyrrolidinohexanophenone): an emerging threat Rosello-Molina, V. Hervas Aparisi, A. Simon Blanes, M. Tejera Nuñez, J. Moreno Soldado, E. Meri Abad, I. Sparano Ros, O. Ribera, C. Esteban, M. De Vicente Muñoz, T. Eur Psychiatry Abstract INTRODUCTION: Alpha-pyrrolidinohexanophenone (α-PHP) is a synthetic cathinone with uneven distribution throughout the world. Its use is not uniformly regulated and its distribution is legal in some European countries. Easily accessible and available through different websites. Synthetic cathinones inhibit monoamine transporters which include dopamine, norepinephrine, and serotonin, resulting in increased neurotransmitter synaptic concentration. Ways of administration show wide range regarding latency period. Onset and appearance of symptoms as well as their duration and intensity may fluctuate. A decreasing order of latency (oral, inhaled, sublingual and intravenous) has been reported. α-PHP can result in the appearance of psychiatric symptoms, include among others, intoxication with sensory perception disturbances and α-PHP -induced psychotic episodes. OBJECTIVES: The aim of our study was to assess the epidemiology, clinical and legal features regarding Alpha-pyrrolidinohexanophenone (α-PHP). METHODS: Review the current bibliography to upgrade the existing knowledge. -Present assorted cases with diverse clinical features. All cases include variability through psychopathological interview, symptoms assessment and treatment response according to rating scales (PANSS, YMRS). -Evaluate different treatment administration ways during acute phase and after hospital discharge. RESULTS: Differences were observed after hospitalization in the response using diverse rating scales. We used antipsychotics to treat intoxication with sensory perception disturbances and α-PHP -induced psychotic episodes. α-PHP had a negative impact on the quality of life of the patients. CONCLUSIONS: α-PHP is a synthetic cathinone with potential risk to mental health and life of users. It is mandatory to implement common legislation all through the European Union to prevent its use and possible implications on population’s mental health. DISCLOSURE: No significant relationships. Cambridge University Press 2022-09-01 /pmc/articles/PMC9565950/ http://dx.doi.org/10.1192/j.eurpsy.2022.1193 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Rosello-Molina, V. Hervas Aparisi, A. Simon Blanes, M. Tejera Nuñez, J. Moreno Soldado, E. Meri Abad, I. Sparano Ros, O. Ribera, C. Esteban, M. De Vicente Muñoz, T. Synthetic cathinone (α-pyrrolidinohexanophenone): an emerging threat |
title | Synthetic cathinone (α-pyrrolidinohexanophenone): an emerging threat |
title_full | Synthetic cathinone (α-pyrrolidinohexanophenone): an emerging threat |
title_fullStr | Synthetic cathinone (α-pyrrolidinohexanophenone): an emerging threat |
title_full_unstemmed | Synthetic cathinone (α-pyrrolidinohexanophenone): an emerging threat |
title_short | Synthetic cathinone (α-pyrrolidinohexanophenone): an emerging threat |
title_sort | synthetic cathinone (α-pyrrolidinohexanophenone): an emerging threat |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9565950/ http://dx.doi.org/10.1192/j.eurpsy.2022.1193 |
work_keys_str_mv | AT rosellomolinav syntheticcathinoneapyrrolidinohexanophenoneanemergingthreat AT hervasaparisia syntheticcathinoneapyrrolidinohexanophenoneanemergingthreat AT simonblanesm syntheticcathinoneapyrrolidinohexanophenoneanemergingthreat AT tejeranunezj syntheticcathinoneapyrrolidinohexanophenoneanemergingthreat AT morenosoldadoe syntheticcathinoneapyrrolidinohexanophenoneanemergingthreat AT meriabadi syntheticcathinoneapyrrolidinohexanophenoneanemergingthreat AT sparanoroso syntheticcathinoneapyrrolidinohexanophenoneanemergingthreat AT riberac syntheticcathinoneapyrrolidinohexanophenoneanemergingthreat AT estebanm syntheticcathinoneapyrrolidinohexanophenoneanemergingthreat AT devicentemunozt syntheticcathinoneapyrrolidinohexanophenoneanemergingthreat |